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Abstract
High-throughput studies constitute an essential and valued source of information for
researchers. However, high-throughput experimental workﬂows are often complex, with
multiple data sets that may contain large numbers of false positives. The representation
of high-throughput data in the Gene Ontology (GO) therefore presents a challenging
annotation problem, when the overarching goal of GO curation is to provide the most
precise view of a gene’s role in biology. To address this, representatives from annotation
© The Author(s) 2019. Published by Oxford University Press.
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teams within the GO Consortium reviewed high-throughput data annotation practices.
We present an annotation framework for high-throughput studies that will facilitate good
standards in GO curation and, through the use of new high-throughput evidence codes,
increase the visibility of these annotations to the research community.

Introduction
The Gene Ontology (GO) is one of the most widely used
computational resources for assigning functional attributes
to genes and their products (1). A standard GO annotation
is made by associating a gene product to a GO term
supported by an evidence code from the Evidence and Conclusion Ontology (ECO) (2) and the data source for that
specific assertion (3). For example, Caenorhabditis elegans
air-2 is annotated to ‘protein serine/threonine kinase activity’ (GO:0004674), with the evidence code ‘direct assay
evidence used in manual assertion’ (ECO:0000314) linked
to the source PMID:15916946. This annotation was based
on an in vitro kinase assay presented in Han et al. (4),
demonstrating that AIR-2 can phosphorylate serine 634 in
TLK-1. The central role of a GO curator is to interpret
the functional data and select terms to best represent a
gene’s role. Curation using the GO relies on careful and
accurate curation to a set of guidelines developed by Consortium participants. Within the GO Consortium (GOC),
curators and ontologists meet frequently to ensure that
practices are reviewed and kept current (1). GO annotation
standards, however, are based on low-throughput experimental set-ups, where the results of experiments can be
interpreted in context, accounting for background knowledge about the gene, experimental hypothesis, physiological
relevance of the assay and other criteria (5). Curation of
high-throughput papers is very different in that it is often
not possible to consider the annotation of each gene on a
case-by-case basis.
For the purposes of this discussion, it is important
to define what characteristics we use to define ‘lowthroughput’ and ‘high-throughput’ studies. In general,
low-throughput studies aim to elucidate the role of
a targeted selection of gene products. These studies
are usually hypothesis driven, with the experimental
design founded on previous knowledge. The workflow tends to be a series of small-scale experiments
that either approach the same biological question in
multiple ways and/or incrementally extend the characterization to build a more complete biological model.
It should first be noted that high-throughput studies encompass a wide variety of experimental
methodologies, and those amenable to functional annota-

tion using the GO represent a small subset of such studies.
Most high-throughput studies, for example genome-wide
association studies and drug screens, fall outside of the
remit of the GO curator. Typically, high-throughput experiments apply the same workflow to a large number of genes/gene products often using an automatic or semi-automatic
methodology and may provide little or no secondary
validation of the results for individual gene products.
They address open-ended questions rather than hypothesisdriven questions and the data is usually presented as a data
set with the same property assigned to genes/gene products
that fall within a given measurement range.
Over the 20 years that GO has been active, there has
been a steady increase in the number of publications that
contains data generated using high-throughput workflows.
With advances in instrumentation and the push to understand complex systems, this growth is set to continue. With
the increase in high-throughput data comes the need to
usefully disseminate such data to the research community,
and to make it FAIR (findable, accessible, interoperable
and reusable) (6), such that it can usefully inform ongoing
research. For many high-throughput data types, numerous consortia and groups, such as the ProteomeXchange
consortium (7), have defined data exchange formats and
established standards to describe data. However, for many
other high-throughput experiments, data standards do not
exist, or, if they do exist, the standards reported often do not
include any confidence thresholds, particularly for purely
qualitative data sets. The challenge for GO curation is
thus to extract useful and accurate annotations from highthroughput data sets that are informative about the physiologically relevant aspects of gene function: biological process, molecular function and cellular component, in a way
which minimizes the addition of erroneous annotations.
Despite the increasing number of high-throughput
papers, clear guidance on how to curate such data using the
GO was lacking. As a result, practices among annotation
groups had diverged resulting in inconsistent annotation,
inclusion of likely false positives and inconsistent use of
evidence codes. Recognizing this, the GOC reviewed its
policy to provide a high-throughput annotation framework
and a new set of evidence codes that allow clear identification of annotations derived from high-throughput data
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sets and a set of guidelines to ensure consistent standards
of curation for these data. Finally, existing high-throughput
annotations were identified and reviewed using the new
framework.

Consultation with GO annotation groups highlighted differences in how they approached high-throughput data.
Some groups only annotated data sets to GO they deemed
of high value to their principal research community, others
had opted to annotate high-throughput data through different curation streams and others excluded high-throughput
papers altogether. For example, the Saccharomyces Genome
Database (SGD) curated high-throughput data sets for GO
using internal guidelines, first developed in 2003 and further refined as large-scale studies, became more common.
These annotations were displayed on individual gene pages
at SGD separated from the manually curated annotations
and clearly marked as having been derived from highthroughput studies. They were made using conventional
evidence codes, with an additional ‘high-throughput’ label
in the SGD database.
A review of data in GO showed that the primary
problem associated with the use of high-throughput data
as a basis to make GO annotations stemmed from the
large numbers of erroneous annotations that can be generated from a single study (8). Two main sources of
erroneous annotation were identified. First, all highthroughput data sets contain false positives to a degree,
which is usually difficult to establish, and, thus curating
this data will generate some incorrect annotations. Some
high-throughput studies incorporate multiple experimental
steps or computational analyses to reduce the level of
false positives, but many other studies are not sufficiently rigorous in the identification of false positives
to provide the level of certainty required for inclusion in the GO database (see Case study 1). Second,
as with low-throughput data, errors may arise from the
selection of the incorrect term by the curator, but because
of the large number of annotations generated, the impact
may be orders of magnitude higher (see Case study 2).
Given the problems with attaching functional attributes
to entities from high-throughput studies, the GOC considered whether there should be an embargo on annotating
such data using the GO. However, this inflexibility would
be a disservice to the curation and research user base. Some
high-throughput data sets may provide comprehensive coverage of a particular area of biology not readily tractable
by other methods, and, for some genes, such screens provide
the only functional data available. Indeed, many annotation
groups indicated strongly that they wanted to retain GO

annotation of existing high-value data sets, and groups
continue to make annotations from new high-throughput
papers when they fill a particular knowledge gap. For
example, the global analysis of protein localization using
green fluorescent protein tagging in fission yeast provides
extensive coverage, 4431 proteins, corresponding to ∼90%
of the proteome (9). This data set was annotated using
terms from the GO cellular component aspect by PomBase in 2009 and still includes many proteins that are as
yet uncharacterized by low-throughput techniques. Despite
containing some false positives, this data set has been of
high value to the primary research community, providing
an often cited starting point for the subsequent functional
analysis of many novel proteins.
Thus, the GOC concluded that although there are
examples of high-throughput studies that were not suitable
for annotation with GO, other studies can produce highvalue annotation, meeting the standards that would allow
a curator to assign functional attributes with the degree of
confidence required. To facilitate the annotation of highthroughput data sets, GO should provide a mechanism
to: (i) clearly distinguish annotations derived from highthroughput workflows and (ii) provide annotation guidelines to help maintain curation accuracy and consistency.

New high-throughput evidence codes
In high-throughput studies, the same functional property is
usually applied to all gene products that fall within a given
value bin or classification and therefore assigned GO terms
as a set. As annotations from high-throughput papers were
previously described using conventional GO evidence codes
for experimental data (3), each independent annotation was
indistinguishable from those derived from low-throughput
studies and the high-throughput provenance was invisible
to most users of the GO. Evidence codes are often used as
a proxy for confidence, and while it does not follow that a
particular annotation derived from an automated computational pipeline is less correct, users tend to give greater
weight to experimental evidence. The same is true when
comparing high- and low-throughput data, users may use
the experimental provenance inform their interpretation.
To allow this discrimination to be made by consumers of
GO, five new evidence codes to describe high-throughput
experiments have been formulated in concert with the
ECO (2). The new codes mirror conventional experimental evidence codes (Table 1) and, in ECO, are children
of ‘high throughput evidence used in manual assertion’
(ECO:0006056; Figure 1), and their low-throughput equivalent, e.g. ‘high throughput direct assay evidence used in
manual assertion’ (ECO:0007005) is a child of ‘direct assay
evidence used in manual assertion’ (ECO:0000314).
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Table 1. High-throughput evidence codes
Term name

Three-letter GO
abbreviation

LTP equivalent
ECO ID

LTP equivalent term name

Three-letter GO
abbreviation

ECO:0006056

High throughput evidence used
in manual assertion
High throughput mutant
phenotype evidence used in
manual assertion
High throughput genetic
interaction evidence used in
manual assertion
High throughput direct assay
evidence used in manual
assertion
High throughput expression
pattern evidence used in manual
assertion

HTP

ECO:0000269

EXP

HMP

ECO:0000315

Experimental evidence used
in manual assertion
Mutant phenotype evidence
used in manual assertion

HGI

ECO:0000316

Genetic interaction evidence
used in manual assertion

IGI

HDA

ECO:0000314

Direct assay evidence used
in manual assertion

IDA

HEP

ECO:0000270

Expression pattern evidence
used in manual assertion

IEP

ECO:0007001

ECO:0007003

ECO:0007005

ECO:0007007

IMP

Five new high-throughput evidence codes added to the Evidence and Conclusion Ontology for GO curation are shown in the first two columns (ECO identifier and term name). These are
shown next to the equivalent conventional (labeled LTP) term. The standard GO three-letter abbreviation is shown for each code (EXP (Inferred from Experiment), IDA (Inferred from
Direct Assay), IMP (Inferred from Mutant Phenotype), IGI (Inferred from Genetic Interaction) and IEP (Inferred from Expression Pattern)). The new high-throughput evidence codes were
chosen specifically to mirror those used in conventional GO annotation, so that retrofit of data would be straightforward—many databases use the conventional GO evidence codes and the
standard GO annotation exchange file, the gene association file, uses the three-letter GO abbreviation (http://geneontology.org/page/go-annotation-file-formats). Going forward, as groups
adopt the gene product association data exchange format for GO annotations, which directly uses ECO codes, there is scope to expand the set of high-throughput evidence codes used by
GO curators to capture the specific types of assay used in high-throughput studies, such as immunofluorescence confocal microscopy or functional complementation evidence. Curators that
wish to expand the set of high-throughput ECO codes should submit requests directly to ECO http://www.evidenceontology.org/submit_term_request/.
Abbreviations: Evidence and Conclusion Ontology identifier (ECO ID), low throughput (LTP).

Clearly marking annotations with high-throughput evidence codes makes the supporting evidence for the annotations more transparent, allows users to weigh them against
conflicting or supporting data and to place them within the
context of a wider study. Crucially, since the GO is often
used to analyze high-throughput data, these data can now
be excluded when analyzing or validating data derived from
a similar experimental protocol, to avoid reinforcing
systematic errors (8). It should be noted that no highthroughput evidence code equivalent to ‘physical interaction evidence used in manual assertion’ (‘IPI’, ECO:00003
53) was instantiated as no high-throughput data sets of
this type had been used to directly make GO assignments.
One reason for this is that GO curators usually look for
more supporting evidence that an individual interaction
is direct to annotate to protein binding (GO:0005515)
or its children. In addition, many databases have their
own curation stream for physical interactions and/or these
data are captured by specialized molecular interactions
resources. Indeed, binary molecular interactions are more
comprehensively covered by dedicated curation flows, and
curation of high-throughput physical interactions using the
GO would lead to duplication of curation effort (10).

Guidelines to support curation of
high-throughput data
The GOC have produced annotation guidelines to accompany the use of high-throughput evidence codes by GO

curators. These are available on the GOC wiki [http://
wiki.geneontology.org/index.php/Inferred_from_High_
Throughput_Experiment_(HTP)]. To ensure consistency
across GO, the same basic annotation standards apply to all
experimental studies, regardless of throughput, following
the existing guidelines developed by the GOC for experimental evidence codes (5) (http://wiki.geneontology.org/
index.php/Guide_to_GO_Evidence_Codes#Experimental_
Evidence_Codes).
Below are four basic rules for good curation practices of
high-throughput data using the GO:

1. Only annotate data with a low false-positive rate: to be
suitable for annotation it is especially important that
the authors have designed the experiment to minimize
the likelihood of false positives. For example, the careful
design of experimental set-up, repeated testing, verification by independent screening methods, high-scoring
threshold, low false-discovery rate cut-off, identification
and exclusion of common contaminants/housekeeping
genes and multivariate data analysis (see Case study 3)
can all lower the false-positive rate to an acceptable level
for annotation.
2. High-throughput data sets do not need to be annotated
as a whole set: it should be noted that GO is not
a repository for high-throughput data sets—there are
more appropriate services dedicated to data housing and
displaying which genes/gene products are part of a data
set. GO curators can incorporate subsets of annotations
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derived from high-throughput experiments where they
meet the correct criteria, adding high-value biological
knowledge of a system. In many instances, data subsets are generated by extra screening steps. Curators
may also use statistical cut-offs to select a subset for
annotation.
A major part of GO curation is the review of existing
annotations to ensure that they most accurately represent current biological knowledge. As with conventional
annotations, it is expected that annotations evidenced
with a high-throughput evidence code can be removed
if shown to be incorrect, for example, in the light
of new information. The addition of high-throughput
evidence codes makes it easier to identify if erroneous
annotations come from a high-throughput data set and,
in some cases, spotting an obvious outlier should trigger a review of the whole set. Importantly, individual
entries from a high-throughput data set can be deleted

from the GO annotated data set over time if they are
known to be false positives, as part of the ongoing
quality assurance process (1).
3. Choose the term with care: as with conventional
annotation, curators must assess whether they can
confidently assign a GO term based on the experimental output. The term chosen should be directly
applicable to the biological question. This is particularly important when dealing with phenotype data—
many observed phenotypes are not necessarily indicative of direct involvement in the specific biological
processes affected (see Case study 2). For example,
an observed increase in cell number may arise from
the disruption of any number of biological processes
and should not be interpreted as a readout for genes
directly involved in the regulation of cell division. In
such cases, the data is better captured by phenotype
annotation.
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Figure 1. High-throughput evidence codes to support GO curation. The ﬁve new evidence codes added to the Evidence and Conclusion Ontology
for GO curation are shown in red boxes: the parent term ‘high throughput evidence used in manual assertion’ (ECO:0006056) and four child terms.
Is a relationships with other classes in the Evidence & Conclusion Ontology are shown, including the evidence equivalents used in conventional
GO annotation (yellow boxes). The new high-throughput evidence codes should be used by GO curators when annotating high-throughput data
in accordance with GOC annotation guidelines. The graph layout was generated using the Ontology Lookup Service (https://www.ebi.ac.uk/ols/index)
OLS-graphview.
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Current status of high-throughput
annotations in GO
Potential contributors of high-throughput annotations were
identified by a search of QuickGO for papers with associated with a high number of annotations (≥65). Of 15 potential contributors identified, 13 annotation groups took part
in a review of annotation sets for high-throughput data.
Papers that contained ≥40 annotations to the same evidence
code were selected for review—this cut-off was chosen
to capture as many high-throughput papers as possible
without generating unmanageably high false positive rates
for reviewers. For participating annotation groups, 380
publications, representing 72 905 annotations, were identified for a review (of 417 publications; 73 028 annotations
overall) and, of these, 298 have been reviewed. A total of
178 papers contained high-throughput data, but, for 39, the
data did not meet the annotation standards provided in the
guidelines and the corresponding annotations were deleted
from GO. The annotations for 120 reviewed papers did
not require re-annotation and retained their conventional
evidence codes. These were usually related to papers covering in-depth characterization genes, gene families or pathways/processes with many different GO terms. Many of the
participating groups have completed the revision of highthroughput paper annotations, updating evidence codes
to the high-throughput equivalents. There are currently
34 533 high-throughput-evidenced annotations from 144
research publications across 23 species in the GO database.

This represents 4.5% of the total number of experimentally
evidenced annotations (764 600) in the GO database (data
from AmiGO, 2018-12-02; 10.5281/zenodo.1899458).

Conclusion
The GOC provides an excellent forum for annotation
groups to review and harmonize curation practices. By
reviewing GO annotations derived from high-throughput
studies, the GOC has provided a framework to aid annotation consistency and allow GO curators to confidently
annotate papers containing valuable data from highthroughput studies without the need for extra training.
The major difference in how a GO curator approaches
high-throughput versus low-throughput publications is
the investment of time in the decision to curate—curators
should examine all aspects of the workflow: experimental
design, controls, data handling, validation and statistics.
From this, the curator must decide whether the data
is amenable to functional annotation and whether the
statistical measures can be used to extract a higher
confidence subset of gene products for annotation.
Nevertheless, some high-throughput studies employ very
complex methodology and statistics, which make the
confidence level difficult to establish. In these cases,
curators are advised to directly contact the authors
or experts within the research community for advice.
Indeed, experts in the fields of proteomics and RNAi
have made valuable contributions to the high-throughput
annotation guidelines. Within the GOC, discussion and
documentation of challenging high-throughput papers is
encouraged and as curators review and curate more highthroughput publications, they will further contribute to the
GOC guidelines. This is illustrated by the work that the
Functional Gene Annotation team at University College
London is currently undertaking, working with leaders in
the field to develop a common set of standards for the
annotation of extracellular matrix components from highthroughput proteomics studies.
For consumers of GO annotation, previously unable to
differentiate between annotations from hypothesis-driven
gene function studies and those from high-throughput
screens, the high-throughput evidence codes provide a
much-needed level of transparency. Critically, the new
evidence codes provide a mechanism for selecting or
deselecting these annotations. The GO is frequently used in
the analysis of high-throughput studies and being able to
exclude data from large studies will help to avoid biases,
particularly in the case where the results of similar studies
have been annotated using the GO.
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4. Understand the data: high-throughput experiments
can potentially generate large numbers of annotations
and thus potentially skew subsequent analyses. It
is therefore especially important that curators take
time to examine all aspects of the workflow and
undertake a rigorous review of the data presented. Highthroughput experimental workflows are often complex
and multilayered with esoteric tests and standards.
Curators are encouraged to contact the authors of highthroughput papers for advice on the interpretation of
the experimental findings.
Within the high-throughput annotation guidelines,
the GOC has provided some experiment-specific
guidance. For example, for proteomics experiments,
proteins should be identified by a minimum of two
unique peptides [http://wiki.geneontology.org/index.
php/Inferred_from_High_Throughput_Direct_Assay_
(HDA)#Proteomics]. These experiment-specific guidelines will be added to by GO curators as experience in
annotating high-throughput papers grows.
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Case studies
Case study 1: high false-positive rate = high
numbers of erroneous annotations
Publication: proteomic analysis of podocyte exosome-enriched fraction from normal human urine. PMID:23376485
(11).
Summary: proteomic analysis by liquid chromatography–tandem mass spectrometry of proteins from human
urine podocyte-enriched exosome fraction using immunoadsorption to paramagnetic beads coated with a monoclonal antibody against the podocyte-specific complement
receptor type 1.
GO annotations pre-review: 1714 annotations to ‘extracellular exosome’ (GO:0070062), direct assay evidence
used in manual assertion (ECO:0000314).
GO annotations post-review: 0.
Review found: this study identifies proteins from
urine by an immunoadsorption technique to ‘enrich’ for
podocyte exosomes—it does not specifically aim to isolate
and ‘purify’ podocyte exosomes. It is not suitable for
annotation as the experimental workflow results in a significant number of non-exosomal protein contaminations,
which would be impossible to differentiate without
additional studies. This paper has been marked as ‘Not
suitable for annotation’ in the Protein2GO annotation
tool (12).

Case study 2: misinterpretation of experiment =
high numbers of erroneous annotations
Publication: genome-wide analysis of self-renewal in
Drosophila neural stem cells by transgenic RNAi. PMID:
21549331 (13).
Summary: genome-wide transgenic RNAi to identify
genes potentially involved in controlling the balance
between stem cell self-renewal and differentiation in
Drosophila melanogaster neuroblasts. Identify genes
causing visible defects in neuroblast lineages and quantify
phenotypes by measurements of proliferation, lineage, cell
size and cell shape.

GO annotations pre-review: 549 annotations to neurogenesis (GO:0022008), mutant phenotype evidence used in
manual assertion (ECO:0000315).
GO annotations post-review: 0.
Review found: The authors were interested in ‘how
the balance between self-renewal and differentiation is
controlled within a stem cell lineage’ and look for cell
division, growth and proliferation defects. This study is
not sufficiently targeted to allow the confident assignment of GO terms to genes. The phenotypes may arise from
the disruption of any number of processes. No attempt is
made to specifically relate this to neurogenesis alone and
many of these genes are so called ‘housekeeping’ genes. This
paper has been marked as ‘Not suitable for annotation’ in
the Protein2GO annotation tool (12).
This data was better represented by FlyBase phenotype
curation. A total of 608 alleles were curated, resulting in
2196 phenotype annotations.

Case study 3: use of multivariate data analysis to
reduce false positives in organelle isolation
Publication: Mapping organelle proteins and protein complexes in D. melanogaster. PMID:19317464 (14).
Summary: Organelles were partially purified from
Drosophila embryos by density gradient centrifugation.
Trypsin-digested proteins from gradient fractions were
labeled with iTRAQ and analyzed using LC–MS/MS.
Annotations pre-review: 329 annotations to either
plasma membrane (GO:0005886), endomembrane system
(GO:0012505) or mitochondrion (GO:0005739), direct
assay evidence used in manual assertion (ECO:0000314).
Annotations post-review: 318 annotations to either
plasma membrane (GO:0005886), endomembrane system
(GO:0012505) or mitochondrion (GO:0005739), highthroughput direct assay evidence used in manual assertion
(ECO:0007005); 7 annotations (direct assay evidence used
in manual assertion, ECO:0000314).
Review found: The use of multivariate data analysis on
what is a relatively crude preparation reduces the issues
from contaminants, allowing relatively high confidence in
assigning correct subcellular locations. A total of 11 annotations were removed, as the proteins were only identified by a
single unique peptide. The remaining 318 annotations were
updated to a high-throughput evidence code. From fluorescence microscopy studies of individual proteins, seven
annotations were also made using the conventional evidence code. Protein complexes were not annotated from this
study as the authors did not specifically set the experiment
up to address this question, and predicted localization was
used for classification.
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In summary, the provision of a set of new evidence
codes and guidelines will facilitate a higher standard and
consistency in the functional annotation of gene products
identified in high-throughput studies and allow consumers
to clearly differentiate annotations with a high-throughput
provenance.
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